On Tuesday, Shares of Allergan PLC (NYSE:AGN), lost -4.14% to $2.62.00. 3.69 million shares of the company were exchanged.
Researchers presented data at IDWeek from the International Network for Optimal Resistance Monitoring (INFORM) program, one of the largest ongoing surveillance programs in the United States. This program is part of a research effort developed and supported by Allergan plc (AGN) that monitors the prevalence of resistant bacteria and changing trends of resistance, as well as the in vitro activity of antibiotics against these pathogens.
Carbapenem-resistant Enterobacteriaceae (CRE) is one of the three most urgent public health threats identified by the U.S. Centers for Disease Control and Prevention (CDC).1Klebsiella pneumoniae carbapenemase (KPC) producing bacteria are a common subset of CRE bacteria and account for approximately 85 percent of all CRE infections in the U.S.
The INFORM data presented at IDWeek stated that the antibiotic AVYCAZ™ (ceftazidime and avibactam) demonstrated potent in vitro activity against certain common Enterobacteriaceae pathogens isolated from patients with complicated urinary tract infections (cUTI) in U.S. hospitals, counting those caused by certain KPC-producing Gram-negative bacteria, meropenem non-susceptible Klebsiella pneumoniae and isolates demonstrating an extended-spectrum beta-lactamase (ESBL)-phenotype. These pathogens are often resistant to multiple antimicrobial agents, which may be important when limited alternative treatment options are accessible. This analysis also found AVYCAZ was highly active against certain Klebsiella species resistant to other beta-lactam antibiotics, in addition to Pseudomonas aeruginosa, counting the majority of isolates non-susceptible to meropenem.
Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution.
Shares of Amazon.com, Inc. (NASDAQ:AMZN), declined -0.23% to $548.90, during its last trading session.
(AMZN)—In celebration of its fifth year, Amazon Crossing, the literary translation imprint of Amazon Publishing, declared a $10 million commitment over the next five years to enhance the number and diversity of its books in translation. Amazon Crossing is one of the largest publishers of translated literature in the United States, with 77 titles from 15 countries and 12 languages to be published in the United States in 2015. Recently’s declared investment will go toward fees paid to translators over the next five years and increasing the countries and languages represented on the Amazon Crossing list, which since 2010 has comprised of more than 200 titles by authors from 29 countries writing in 19 languages.
To support this growing commitment to books in translation, Amazon Crossing editors recently opened a new website for authors, agents and publishers to suggest titles for translation at translation.amazon.com/submissions. Amazon Crossing is now accepting submissions in mystery, thriller, women’s fiction, historical fiction, literary fiction, memoir, science fiction and fantasy categories.
Amazon.com, Inc. operates as an online retailer in North America and internationally. It operates through the North America, International, and Amazon Web Services (AWS) segments.
At the end of Tuesday’s trade, Shares of Intrexon Corp (NYSE:XON), declined -11.42% to $32.11.
Intrexon Corporation (XON), a leader in synthetic biology, recently declared that ViaGen Pets, a partner of the Company which actively serves pet owners seeking genetic preservation services for their beloved companion animals, has successfully delivered two litters of healthy, cloned kittens for its clients. With its recently accomplished state-of-the-art lab offering unprecedented capabilities, ViaGen Pets is preparing for a global launch of its services in early 2016 providing an opportunity to pet owners worldwide that has never before existed.
Through the combination of Intrexon’s expertise in reproductive technologies and ViaGen’s experience as the trusted world leader in cloned mammals for over 15 years, more affordable options for those who wish to preserve the genetics of their beloved companion animals is near. ViaGen Pets presently has clients across multiple countries that have trusted the Company to deliver a genetic twin of their puppies and kittens and is actively engaging the global veterinary community recently as it develops partnerships to best serve the pet owner.
ViaGen Pets is also committed to affording companion animals the best possible healthcare, both recently and in the future. Safe, long-term preservation of pets’ cells offers owners peace of mind their special breed will have access to current cell-based therapies in addition to therapeutic options that do not yet exist. The Company will provide further information about these and other options to families and veterinarians worldwide as its global launch approaches in early 2016.
Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that comprise of key genetic components.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
